BR112022026720A2 - Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas - Google Patents
Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmasInfo
- Publication number
- BR112022026720A2 BR112022026720A2 BR112022026720A BR112022026720A BR112022026720A2 BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2 BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- methods
- recombinant
- reduced protease
- protease sensitivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047989P | 2020-07-03 | 2020-07-03 | |
| US202163134411P | 2021-01-06 | 2021-01-06 | |
| PCT/US2021/040240 WO2022006492A2 (en) | 2020-07-03 | 2021-07-02 | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026720A2 true BR112022026720A2 (pt) | 2023-01-24 |
Family
ID=79317685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026720A BR112022026720A2 (pt) | 2020-07-03 | 2021-07-02 | Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265406A1 (https=) |
| EP (1) | EP4176056A4 (https=) |
| JP (1) | JP2023532021A (https=) |
| KR (1) | KR20230034320A (https=) |
| CN (1) | CN115803047A (https=) |
| AU (1) | AU2021299565A1 (https=) |
| BR (1) | BR112022026720A2 (https=) |
| CA (1) | CA3173145A1 (https=) |
| IL (1) | IL299559A (https=) |
| MX (1) | MX2023000243A (https=) |
| WO (1) | WO2022006492A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102914621B1 (ko) | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2022150516A1 (en) * | 2021-01-06 | 2022-07-14 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| JP2026509243A (ja) * | 2023-03-10 | 2026-03-17 | ジェネンテック， インコーポレイテッド | プロテアーゼとの融合およびその使用 |
| WO2025217138A1 (en) * | 2024-04-09 | 2025-10-16 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6198807B2 (ja) * | 2012-03-16 | 2017-09-20 | ジェネンテック， インコーポレイテッド | 操作され立体構造的に安定化されたタンパク質 |
| WO2016056913A1 (en) * | 2014-10-10 | 2016-04-14 | Enzypep B.V. | Peptide fragment condensation and cyclisation using a subtilisin variant with improved synthesis over hydrolysis ratio |
| WO2017210445A1 (en) * | 2016-06-03 | 2017-12-07 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| KR102914621B1 (ko) * | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2022150516A1 (en) * | 2021-01-06 | 2022-07-14 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| US20240067729A1 (en) * | 2021-01-06 | 2024-02-29 | Palleon Pharmaceuticals Inc. | Anti-pd-l1 antibodies and fusion proteins thereof |
-
2021
- 2021-07-02 WO PCT/US2021/040240 patent/WO2022006492A2/en not_active Ceased
- 2021-07-02 JP JP2022580142A patent/JP2023532021A/ja active Pending
- 2021-07-02 CN CN202180047881.0A patent/CN115803047A/zh active Pending
- 2021-07-02 EP EP21833741.8A patent/EP4176056A4/en active Pending
- 2021-07-02 US US18/003,234 patent/US20230265406A1/en active Pending
- 2021-07-02 IL IL299559A patent/IL299559A/en unknown
- 2021-07-02 BR BR112022026720A patent/BR112022026720A2/pt unknown
- 2021-07-02 KR KR1020237003002A patent/KR20230034320A/ko active Pending
- 2021-07-02 CA CA3173145A patent/CA3173145A1/en active Pending
- 2021-07-02 AU AU2021299565A patent/AU2021299565A1/en active Pending
- 2021-07-02 MX MX2023000243A patent/MX2023000243A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4176056A4 (en) | 2024-10-30 |
| CN115803047A (zh) | 2023-03-14 |
| WO2022006492A2 (en) | 2022-01-06 |
| JP2023532021A (ja) | 2023-07-26 |
| EP4176056A2 (en) | 2023-05-10 |
| WO2022006492A3 (en) | 2022-02-17 |
| US20230265406A1 (en) | 2023-08-24 |
| AU2021299565A1 (en) | 2023-02-02 |
| IL299559A (en) | 2023-02-01 |
| CA3173145A1 (en) | 2022-01-06 |
| KR20230034320A (ko) | 2023-03-09 |
| MX2023000243A (es) | 2023-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026720A2 (pt) | Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas | |
| MX2020007024A (es) | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. | |
| BR112021026789A2 (pt) | Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas | |
| CL2021000873A1 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. | |
| AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
| PE20210313A1 (es) | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso | |
| BR112022014623A2 (pt) | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos | |
| MX2023011599A (es) | Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. | |
| AU2019218516A1 (en) | Antibodies to T cell immunoreceptor with ig and itim domains (TIGIT) and uses thereof | |
| UY26783A1 (es) | Antígenos de estreptococo. | |
| BR112019000098A2 (pt) | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio | |
| BR112022008817A2 (pt) | Terapias combinadas para tratamento de câncer | |
| JOP20240083A1 (ar) | بروتينات ربط ميزوثيلين واستخداماتها | |
| SA523451800B1 (ar) | Sirp أجسام مضادة لـ ألفا | |
| BR112022022937A2 (pt) | Proteínas de fusão estabilizadas de proteína de pico de coronavírus | |
| DOP2021000145A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| BR112018074759A2 (pt) | artigo absorvente | |
| BR112023024500A2 (pt) | Anticorpo que se liga à proteína associada ao receptor do ativador de plasminogênio tipo uroquinase, conjugado anticorpo-fármaco, polipeptídeo, polinucleotídeo isolado, vetor, célula hospedeira, composição farmacêutica, e, kit | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| BR112022020453A2 (pt) | Anticorpos anti-cd98 e usos dos mesmos | |
| BR112022008653A2 (pt) | Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco | |
| BR112023022774A2 (pt) | Terapias de combinação para tratamento de câncer | |
| CO2022005587A2 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| WO2021151043A3 (en) | Methods and compositions for treating and preventing viral infection | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos |